United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - solifenacin succinate - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - solifenacin succinate - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - solifenacin succinate - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - solifenacin succinate - oral tablet - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - solifenacin succinate - oral tablet - 10mg

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - solifenacin succinate - film-coated tablet - 10 milligram(s) - drugs for urinary frequency and incontinence; solifenacin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - solifenacin succinate - film-coated tablet - 5 milligram(s) - drugs for urinary frequency and incontinence; solifenacin

Ireland - English - HPRA (Health Products Regulatory Authority)

vivanta generics s.r.o. - solifenacin succinate - film-coated tablet - 10 milligram(s) - drugs for urinary frequency and incontinence; solifenacin

Ireland - English - HPRA (Health Products Regulatory Authority)

vivanta generics s.r.o. - solifenacin succinate - film-coated tablet - 5 milligram(s) - drugs for urinary frequency and incontinence; solifenacin

United States - English - NLM (National Library of Medicine)

cipla usa inc. - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate tablets are contraindicated in patients: -   with urinary retention [see warnings and precautions (5.2)] , -   with gastric retention [see warnings and precautions (5.3)] , -   with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5)] , and -   who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions (6.2)] . risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice